Directors’ Report Details of Remuneration for Year Ended 30 June 2014 Table 1. Non-Executive Director Remuneration for the year ended 30 June 2014 There was no performance related remuneration payable to non-executive directors during the year.  Table 2. Remuneration of key management personnel for the year ended 30 June 2014 Short Term Post Employment Equity Total % of  remuneration  consisting of  options Salary & Fees Cash  Bonus Non  Monetary  Benefits Super- annuation Termination  Benefits Options $ $ $ $ $ $ $ Peter Francis 2014 113,328  - - - - 27,556 140,884 19.6% 2013  113,328  - - - - 137,728 251,056  54.9% John Chiplin 2014 53,000 - - - - 6,890 59,890 11.5% 2013 50,000  - - - - 34,444 84,444  40.8% Iain Ross 2014 58,000 - - - - 6,890 64,890 10.6% 2013 50,000  - - - - 34,444 84,444  40.8% Kevin Buchi 2014 53,000 - - - - 103,098 156,098 66.0% 2013 10,972 - - - - - 10,972  0.0% Mel Bridges 2014 58,000 - - - - 6,890 64,890 10.6% 2013 55,000  - - - - 34,444 89,444  38.5% Short Term Post Employment Equity Total % of re   consisting  of options   muneration Perfor- mance  based Salary &  Fees Cash  Bonus Non  Monetary  Benefits Super- annuation Termination  Benefits Options $ $ $ $ $ $ $ Peter French 2014 300,000 150,000 - 17,775 - 126,061 539,836 21.2% 46.5% 2013  249,800   -  - 15,775  - 104,167  369,742 28.2% 28.2% Carl Stubbings 2014 252,000 50,000 - 17,775 - 19,391 339,166 5.7% 20.4% 2013 240,000  -  - 15,775 - 54,166 309,941 17.5% 17.5% Michael Graham 2014 195,000 30,000 - 17,775 - 10,417 253,192 4.1% 16.0% 2013 185,000  -   -  15,775 - 52,083  252,858 20.6% 20.6% David Suhy 2014 217,902 87,160 - - - 25,360 330,422 7.7% 34.1% 2013 135,662  -   -  - - 38,710 174,372 22.2% 22.2% Greg West 2014 217,391 50,000 - 17,775 - 15,461 300,627 5.1% 21.8% 2013 162,333  -   -  14,610 - 2,790  179,733 1.6% 1.6% Fixed  At risk - At risk -  remuneration STI Options Peter French  53.5%  25.3%  21.2% Carl Stubbings  79.6%  14.7%  5.7% Michael Graham  84.0%  11.9%  4.1% David Suhy  65.9%  26.4%  7.7% Greg West  78.2%  16.7%  5.1% Benitec Biopharma Ltd  Annual Report 2014 Page 11